Clinical trials: Influenza Virus
SARS-CoV-2 Infection, Influenza A
SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings
The Metrix COVID/Flu Test will be evaluated for use in Point-of-Care and Non-Laboratory settings in a home testing environment utilizing the clinical study design described herein.
- Conditions
- SARS-CoV-2 Infection, Influenza A, Influenza B
- Trial name
- NCT06191393
- Testing
- Aptitude Medical Systems Metrix COVID/Flu Test
- Where
- 3 sites in United States
- Volunteers
- 614 people
- Sponsor
- Aptitude Medical Systems
Influenza
Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years
This study will evaluate the safety and immunogenicity of VAX161B [STF2.HA5 H5N1], a recombinant, inactivated, subunit influenza vaccine given as a two dose regimen at a range of doses.
- Trial name
- NCT01560793
- Testing
- VAX161 [STF2.HA5 H5N1]
- Where
- 2 sites in United States
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- VaxInnate Corporation
Influenza
A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2008/2009 Influenza Virus Strains for the Northern Hemisphere
A study to assess whether the Northern Hemisphere 2008/2009 season influenza vaccine Inflexal V fulfills the EMEA requirements for re-registration of influenza vaccines
- Trial name
- NCT01303510
- Testing
- Inflexal V
- Where
- Switzerland
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Influenza, Human, Influenza
Clinical Performance of the Diassess Influenza A and B Test
The primary objective of this study is device feasibility of the Diassess Influenza A and B Test
- Conditions
- Influenza, Human, Influenza, Flu
- Trial name
- NCT03035396
- Testing
- Diassess Influenza A and B Test
- Where
- United States
- Volunteers
- 567 people
- Sponsor
- Diassess Inc.
Orthomyxoviridae Infection, Influenza
Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children
Primary Objective: To evaluate for each influenza strain the non-inferiority of Investigational Fluzone vaccine to the standard Fluzone® vaccine in healthy subjects aged 6 to 35 months or 3 to 8 years.
- Conditions
- Orthomyxoviridae Infection, Influenza, Myxovirus Infection
- Trial name
- NCT00391391
- Testing
- Split, Inactivated, Trivalent Influenza Vaccine, Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)
- Where
- 19 sites in United States
- Volunteers
- 520 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza
Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model
A Phase 2, single center, randomized, double blind study evaluating the safety, efficacy, and immunogenicity of MVA NP+M1 in the H3N2 human influenza challenge model; on healthy adult volunteers.
- Trial name
- NCT03883113
- Testing
- MVA-NP+M1, Saline, H3N2 (A/Belgium/2417/2015)
- Where
- Belgium
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Barinthus Biotherapeutics
Healthy
Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy Adults
DNA vaccines consist of small pieces of DNA also known as plasmids, and have several potential advantages over traditional vaccines. Thus far, DNA vaccines appear to be well tolerated in humans.
- Trial name
- NCT01142362
- Testing
- VGX-3400X
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Inovio Pharmaceuticals
Influenza Vaccines
A Randomized Study to Compare the Safety and Immunogenicity of Fluviral® Made With New Versus Aged Bulk
Vaccination is currently the most effective means of controlling influenza and preventing its complications and mortality in persons at risk.
- Trial name
- NCT00586469
- Testing
- Fluviral
- Where
- 8 sites in Canada
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Avian
Safety and Immunogenicity Study of a H5N1 Influenza Vaccine (Vero Cell-Derived, Whole Virus) in Healthy Infants, Children and Adolescents
The purpose of this study is to assess the safety and immunogenicity (i.e. primary immune response, immunogenicity of two different doses, antibody persistence 360 days after the first vaccination, immune response to a…
- Trial name
- NCT01052402
- Testing
- H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation
- Where
- 20 sites in Australia, Finland and 2 more
- Volunteers
- 684 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Vaccine Response
Probiotics and Influenza Vaccination Response
Assess efficacy of oral ingestion of a probiotic product on immune function in a population of healthy adult men and women in a clinical vaccination study.
- Trial name
- VERB (NCT05690373)
- Testing
- Probiotic effect on influenza vaccine response
- Where
- Netherlands
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- The Archer-Daniels-Midland Company
Healthy
A Prospective Study to Evaluate the Safety of a New Monovalent Intranasal Influenza Vaccine
This prospective annual release study was designed to assess the safety of a monovalent influenza virus vaccine using a new strain recommended for the 2009-2010 influenza season not previously contained in the trivalent…
- Trial name
- MI-MA205 (NCT00873912)
- Testing
- Monovalent influenza virus vaccine
- Where
- 3 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza Disease
Support Annual Strain Update, Safety and Immunogenicity of an Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008, When Administered to Subjects 18-64 Years Affected by Chronic Diseases.
This phase II, open label, is designed as a seasonal study to support annual strain update evaluating the safety, clinical tolerability and immunogenicity of the 2007-2008 formulation of Novartis Vaccines' adjuvanted, subunit…
- Trial name
- NCT00522067
- Testing
- Adjuvanted influenza vaccine
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- Novartis Vaccines
COVID-19, Coronavirus Disease 2019
A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza
The main purpose of this study is to understand: the symptoms of COVID-19 or influenza- health-related outcomes of people with COVID-19 or influenza (influenza only included in updated study analyses) the potential effects of…
- Conditions
- COVID-19, Coronavirus Disease 2019, Influenza
- Trial name
- NCT05160636
- Testing
- COVID-19 Vaccine
- Where
- United States
- Volunteers
- 999 people
- Sponsor
- Pfizer
Influenza
Study Comparing Immune Response to, and Safety of, Fluviral and Fluzone Influenza Vaccines in Persons 50 y.o. and Over
The goal of this study is to determine whether the immune responses induced by Fluviral, the investigational vaccine, are comparable to those induced by Fluzone, which is an influenza vaccine currently licensed in the U.S.
- Trial name
- NCT00232947
- Testing
- Influenza virus vaccine (Fluviral), Influenza virus vaccine (Fluzone)
- Where
- 10 sites in United States
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- ID Biomedical Corporation, Quebec
Influenza
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults
This trial will assess the immunogenicity and safety of GSK Biologicals' vaccine GSK1557484A, prepared from old concentrated monobulk material, in adults aged 18 to 64 years, when administered up to 5 years following production.
- Trial name
- NCT01416571
- Testing
- Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Safety Issues, Effect of Drug
ADC189 Tablets on Influenza A Virus Infection/Influenza B Virus Infection
The goal of this Phase II/III study is to investigate the safty and efficacy of ADC189 tablets in adolescents and adults with influenza A virus infection/influenza B virus infection.
- Trial name
- ADC (NCT06342921)
- Testing
- 15 mg ADC189, 45 mg ADC189
- Where
- China
- Volunteers
- 749 people
- Sponsor
- Jiaxing AnDiCon Biotech Co.,Ltd
Influenza
Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine
This trial will assess the immunogenicity and safety elicited by the adjuvanted GSK Biologicals' (pre-) pandemic influenza candidate vaccine in healthy Japanese adults.
- Trial name
- NCT00742885
- Testing
- Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
- Where
- 2 sites in Japan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza Disease
Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2009/2010 Recommended in Northern Hemisphere in Non-elderly Adult and in Elderly Subjects
Annual trial for registration influenza vaccine with the strain composition for season 2009/2010.
- Trial name
- NCT00918268
- Testing
- Influenza vaccine
- Where
- 3 sites in Italy
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months
This study assesses immunogenicity and safety of NBP607-QIV to Agrippal which are indicated for active immunization for the prevention of influenza disease.
- Trial name
- NCT03704740
- Testing
- NBP607-QIV, Agrippal
- Where
- South Korea
- Volunteers
- 676 people, healthy volunteers welcome
- Sponsor
- SK Bioscience Co., Ltd.
Influenza, Human
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
This Phase 3 study is a randomized, observer-blind study of MF59-adjuvanted influenza vaccine (aQIV or aTIV) compared with a non-adjuvanted influenza vaccine (QIV or TIV) in adults ≥65 years of age.
- Trial name
- NCT06087640
- Testing
- aQIV or aTIV, QIV or TIV
- Where
- 255 sites in United States, Australia and 19 more
- Volunteers
- 38,769 people, healthy volunteers welcome
- Sponsor
- Seqirus
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.